Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis.
Trabanelli S
Nat Commun. 2017 Sep 19;8(1):593. doi: 10.1038/s41467-017-00678-2
Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.
Broccoli A
Haematologica. 2017 Aug 3;102(11):1931-1935. doi: 10.3324/haematol.2017.171355
Estrogen receptor β ligation inhibits Hodgkin lymphoma growth by inducing autophagy.
Pierdominici M
Oncotarget. 8(5):8522-8535. doi: 10.18632/oncotarget.14338
Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma.
Castagna L
Bone Marrow Transplant. 2017 Jan 16;52(5):683-688. doi: 10.1038/bmt.2016.348
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.
Merryman RW
Blood. 2017 Jan 10;129(10):1380-1388. doi: 10.1182/blood-2016-09-738385
Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation.
Locatelli SL
Sci Rep. 2016 Oct 21;6:35745. doi: 10.1038/srep35745
Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation.
Castagna L
Bone Marrow Transplant. 2016 Oct 17;51(12):1644-1646. doi: 10.1038/bmt.2016.257
The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest.
Locatelli SL
Leukemia. 2016 Aug 8;30(12):2402-2405. doi: 10.1038/leu.2016.224
Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.
Santoro A
J Clin Oncol. 2016 Jul 5;34(27):3293-9. doi: 10.1200/JCO.2016.66.4466
The patient’s CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide.
Crocchiolo R
Bone Marrow Transplant. 2016 Mar 21;51(8):1134-6. doi: 10.1038/bmt.2016.69